论文部分内容阅读
目的:研究地塞米松(DXM)对恶性造血细胞表面Flt3受体表达及重组人Flt3配体(rhFL)介导的恶性造血细胞增殖的影响。方法:采用流式细胞仪分析18株恶性造血细胞系细胞和10例新鲜白血病原代细胞表面Flt3受体的表达,及与DXM 0.1μmol/L共育24h后Flt3受体的表达,用NTT法测定DXM对rhFL介导的恶性造血细胞增殖的影响。结果:(1)恶性造血细胞系细胞和白血病原代细胞Flt3受体的表达广泛并呈多样性。(2)恶性细胞表面Flt3受体的表达与rhFL介导的恶性细胞增殖无一定相关性,rhFL促进部分Flt3受体阴性细胞的增殖。(3)DXM下调Flt3受体的表达,抑制rhFL介导的部分恶性造血细胞系细胞和新鲜白血病原代细胞的增殖。结论:DXM可下调恶性造血细胞表面Flt3受体的表达,抑制rhFL介导的恶性造血细胞的增殖。DXM和rhFL联合应用,可使rhFL在恶性造血系统疾病的造血功能缺乏治疗时更为安全。
Objective: To investigate the effect of dexamethasone (DXM) on the expression of Flt3 receptor on the surface of malignant hematopoietic cells and the proliferation of malignant hematopoietic cells mediated by recombinant human Flt3 ligand (rhFL). Methods: The expression of Flt3 receptor on 18 malignant hematopoietic line cells and 10 fresh leukemia primary cells was analyzed by flow cytometry. The expression of Flt3 receptor was detected after incubated with DXM 0.1 μmol / L for 24 hours. The effect of DXM on rhFL-mediated proliferation of malignant hematopoietic cells was determined. Results: (1) The expression of Flt3 receptor in malignant hematopoietic cell line and leukemia primary cell was extensive and varied. (2) The expression of Flt3 receptor on the surface of malignant cells was not correlated with the proliferation of rhFL-mediated malignant cells. RhFL promoted the proliferation of some Flt3 receptor negative cells. (3) DXM down-regulated the expression of Flt3 receptor, and inhibited the proliferation of rhFL-mediated cells in some malignant hematopoietic lineage cells and fresh leukemia cells. Conclusion: DXM can down-regulate the expression of Flt3 receptor on the surface of malignant hematopoietic cells and inhibit the proliferation of malignant hematopoietic cells induced by rhFL. The combination of DXM and rhFL allows rhFL to be safer in the absence of treatment of hematopoietic malignancies.